Navigation Links
Exiqon A/S: Interim Report for the Period 1 January - 30 June 2008 (Unaudited)
Date:8/28/2008

VEDBAEK, Denmark, August 28 /PRNewswire-FirstCall/ -- Strong organic growth continued in Q2 2008 supported by new research product offerings. The development of Exiqon's first molecular diagnostic product based on miRNA profiling remains on track for year end launch.

- Revenue in Q2 2008 increased by 139% on the year-earlier period to DKK

28 million, totaling DKK 44.5 million in the first six months of 2008.

- Product sales in Q2 2008 increased by 239% on the same period last year

to DKK 26.3 million (including research product sales and diagnostic

sales) totaling DKK 40.5 million in the first six months of 2008.

Research product sales grew organically by 70% compared to Q2 2007.

- Direct contribution margin in Q2 2008 was 65% compared to 78% in the

same period last year, totaling 66% in the first six months of 2008.

Gross margin was 25% compared to 64% in the same period last year,

totaling 33% in the first six months of 2008. The gross margin was

affected by new product offerings and cost of unused capacity during the

current build-up phase.

- Total operating expenses in Q2 2008 increased by 80% on the same period

last year to DKK 48.3 million, totaling DKK 82.7 million in the first six

months of 2008. The increase in operating expenses is primarily due to

the acquisition of Oncotech Inc.

- Net loss for Q2 2008 was DKK 38.8, totaling DKK 63.5 million the first

six months of 2008. EPS amounted to DKK -1.37 in Q2 2008 and DKK -2.25 in

the first six months of 2008.

- Based on current activities, the financial guidance for 2008

is retained with revenue of DKK 140-150 million in 2008 including both

research product sales and diagnostic sales. A net loss of DKK 100-115

million is expected, for the full year 2008, including the effect of

costs of current incentive plans in the amount to DKK 6 million.

L
'/>"/>

SOURCE Exiqon A/S
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Exiqon Receives the 2008 Frost & Sullivan Growth Strategy Leadership Award
2. Exiqon Appoints Cynthia French as Chief Scientific Officer and Erik Holmlin as Chief Commercial Officer
3. Exiqon: Major Shareholder Announcement
4. Arpida Reports Interim Results for Six Months to 30 June 2008
5. Bavarian Nordic A/S - Interim Report for the Period 1 January to 30 June 2008
6. LPBP Inc. - Re-filing certification of interim filings
7. Fufeng Announces 2008 Interim Results With Strong Sign of Recovery
8. BioMS Medical announces positive interim analysis on phase III trial of dirucotide (MBP8298) for multiple sclerosis
9. Chromos obtains interim order in connection with arrangement, announces annual and special meeting of shareholders and confirms mailing of information circular
10. Quest PharmaTech Announces Interim Results from Phase I/II Clinical Trial for Photodynamic Treatment for Hair Removal
11. Angiotechs corporate partner, Cook Medical, announces positive interim results for its Zilver(R) PTX(TM) clinical study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... -- New open access, ... serving the international surgical community ... technical, and medical information products and services, today announced ... Surgery Open ( IJS Open ), a ... This peer-reviewed, online-only journal will make significant contributions to ...
(Date:8/4/2015)... (PRWEB) , ... August 04, 2015 , ... On August ... inviting a diverse selection of entrepreneurs from across the United States to talk about ... Richman is honored to be chosen to be among the attendees. , One of ...
(Date:8/3/2015)... 3, 2015  Halozyme Therapeutics, Inc. (NASDAQ: HALO ... the second quarter 2015 on Monday, August 10, 2015 ... Torley , president and chief executive officer, will lead ... release financial results for the second quarter 2015. ... "Investors" section of Halozyme,s corporate website and a recording ...
(Date:8/3/2015)... -- MiMedx Group, Inc. (NASDAQ: MDXG ), the leading ... processes to develop and market advanced products and therapies ... Ophthalmic and Dental sectors of healthcare, announced today that ... Canaccord|Genuity Growth Conference in Boston, Massachusetts ... William C. Taylor , President and COO, and ...
Breaking Biology Technology:Elsevier Announces the Launch of International Journal of Surgery Open 2Elsevier Announces the Launch of International Journal of Surgery Open 3Elsevier Announces the Launch of International Journal of Surgery Open 4White House Invites uBiome CEO Jessica Richman to First-Ever Startup Demo Day 2Halozyme to Host Second Quarter 2015 Financial Results Conference Call 2MiMedx To Present At 35th Annual Canaccord|Genuity Growth Conference 2
... (Nasdaq:,SIAL) announced today the global release of ... researchers to reproducibly,interrogate gene function, via siRNA ... not been considered amenable to conventional lipid-based,siRNA ... reagents exhibit a number,of drawbacks, including high ...
... DIEGO, Oct. 18 Volcano Corporation,(Nasdaq: VOLC ) ... shares of its common stock at a price of ... by Volcano. Volcano has granted the,underwriters a 30-day option ... common stock to cover over-allotments, if any. The offering,is ...
... Oct. 17 AMICAS, Inc. (Nasdaq: AMCS ),a ... today announced it will present to and meet with ... being held in New,York. (Logo: http://www.newscom.com/cgi-bin/prnh/20060202/AMICASLOGO ... -- Presentation begins promptly at 10:20 a.m. (Eastern ...
Cached Biology Technology:Sigma-Aldrich Introduces N-TER Nanoparticle siRNA Transfection System for Delivery of siRNA Into Difficult-to-Transfect Cell Types 2Volcano Corporation Announces Pricing of Common Stock Offering 2
(Date:7/21/2015)... OXFORD, Connecticut , July 21, 2015 /PRNewswire/ ... the "Company"), a biometric authentication company focused on ... the Wocket® smart wallet, announces that it has ... Tokenization System and Method. This ... that not only authorizes an account, but also ...
(Date:7/13/2015)... , July 13, 2015 Synaptics Inc. ... human interface solutions, today announced sampling of ClearPad ... display driver integration (TDDI) product targeting smartphones and ... to combine Synaptics , best-in-class touch controller ... driver technology developed in the company,s Japan Design ...
(Date:7/9/2015)... 2015 Research and ... the "Biometrics for Banking; Market & Technology ... to their offering. The adoption for ... growth and the forecast is that by 2020 ... companies involved in delivering biometric systems to the ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 2Global Banking Biometrics Market 2015-2020 - Market & Technology Analysis, Adoption Strategies and Forecasts 3
... elderly people from benefiting equally from exercise, no matter ... published in today's (Aug. 10) Journal of the American ... who exercised stayed healthier than their couch potato peers, ... most from physical activity, said Marco Pahor, M.D., director ...
... a single gene, Nrf2, plays a critical role in ... by Shyam Biswal, PhD, at the Johns Hopkins Bloomberg ... exacerbated allergen-mediated asthma in mice models. The study’s findings, ... Journal of Experimental Medicine, may hold therapeutic potential for ...
... future hopes for human applications , Israeli scientists report ... successfully transplanted whole frozen and thawed ovaries in sheep, ... the laboratory into early embryonic development. , Follow-up tests ... which oocytes were recovered were still functioning normally three ...
Cached Biology News:Exercise aside, genes may ultimately dictate seniors' mobility 2Exercise aside, genes may ultimately dictate seniors' mobility 3Researchers Discover Gene That Determines Asthma Susceptibility By Regulating Inflammation 2Israeli scientists successfully transplant frozen-thawed ovaries in sheep 2Israeli scientists successfully transplant frozen-thawed ovaries in sheep 3
... I (RNase-free) (E.C. 3.1.21.1) is a nonspecific ... chromatin. It functions by hydrolyzing phosphodiester linkages, ... and a 3'-hydroxyl group. Ambion's RNase-free DNase ... and is recommended to degrade DNA in ...
Rabbit polyclonal antibody to Neuromedin U Receptor 1 (GPR66)...
... Perhaps sheer in-house demand is causing ... want your precious antibody. This can cause ... • Receive royalties for your hard ... and let us build it up and ...
... (rat) - Diluted Antiserum for RIA, Host: ... U-23 (rat) Immunology Products, Host: Rabbit ... our corresponding peptide and 1 ... Neuromedin U-23 (rat) (H-9295) and ([ 1 ...
Biology Products: